v3.26.1
Other Non-current Assets - Narrative (Details)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
USD ($)
payment
Jun. 30, 2025
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2026
USD ($)
payment
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
payment
Intangible Asset, Finite-Lived, Acquired [Line Items]              
Revenues $ 13,819 $ 10,003     $ 28,265 $ 18,723  
Number of guaranteed royalty payments | payment 8            
License agreement with Sunovion Pharmaceuticals, Inc.              
Intangible Asset, Finite-Lived, Acquired [Line Items]              
Minimum annual royalty receivable $ 1,000     $ 1,000 $ 1,000    
Number of annual royalty payments receivable | payment 2       2   3
Royalty              
Intangible Asset, Finite-Lived, Acquired [Line Items]              
Revenues         $ 976   $ 938
Royalty | License agreement with Sunovion Pharmaceuticals, Inc.              
Intangible Asset, Finite-Lived, Acquired [Line Items]              
Revenues     $ 8,000 $ 8,000